BCAB
BioAtla (BCAB)
$21
About BioAtla (BCAB)
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Details
Daily high
$0.22
Daily low
$0.19
Price at open
$0.19
52 Week High
$1.43
52 Week Low
$0.14
Market cap
13.5M
Dividend yield
0.00%
Volume
809,350
Avg. volume
3.5M
P/E ratio
-.18
BioAtla News
Details
Daily high
$0.22
Daily low
$0.19
Price at open
$0.19
52 Week High
$1.43
52 Week Low
$0.14
Market cap
13.5M
Dividend yield
0.00%
Volume
809,350
Avg. volume
3.5M
P/E ratio
-.18